Kymera Therapeutics, Inc. KYMR 深 沪
已收盘 05-22 16:00:00 美东时间
78.89
-1.720
-2.13%
华盛通- 最 高81.15
- 今 开79.76
- 成交量 54.94万股
- 最 低 78.32
- 昨 收 80.61
- 总市值 64.89亿
- 52周最高 103.00
- 市盈率 静 --
- 换手率 0.67%
- 52周最低 36.65
- 委 比 59.84%
- 总股本 8225.76万
- 历史最高 103.00
- 量 比 1.03
- 振 幅 3.51%
- 历史最低 9.60
- 每 手 1
- 风险率 17.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kymera Therapeutics Announces Presentations On Results From KT-621 Clinical Trial At Annual Meetings May 13-16
Society for Investigative Dermatology (SID) 2026 Annual MeetingTitle: KT-621 Treatment Induces Rapid STAT6 Degradation and Modulation of Th2 Gene Transcripts in Atopic Dermatitis Lesional SkinType/Session: Oral
05-15 19:06
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses
Kymera Therapeutics announced positive Phase 1b clinical data for KT-621, an oral STAT6 degrader, in treating Type 2 inflammatory diseases like atopic dermatitis and asthma. Results showed significant STAT6 degradation, reduction of inflammatory biomarkers, and clinical improvements, with favorable safety profiles. KT-621 is currently in Phase 2b trials for atopic dermatitis and asthma, with data expected in mid-2027 and late 2027, respectively. ...
05-15 11:00
美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
Kymera Therapeutics will participate in fireside chats at the Bank of America 2026 Healthcare Conference in Las Vegas on May 12 and the RBC Capital Markets 2026 Global Healthcare Conference in New York on May 19. Live webcasts and replays will be available on the Company’s website. Kymera is a clinical-stage biotech company advancing targeted protein degradation therapies for immunological diseases.
05-06 11:00
Jeito Capital appoints Elaine Caughey partner for business development, investor relations
Jeito Capital appoints Elaine Caughey partner for business development, investor relations Jeito Capital named Elaine Caughey partner for business development and investor relations, strengthening dealmaking support for portfolio companies and expanding investor engagement. Caughey was deputy chief
05-05 17:46
财报速睇 | Kymera Therapeutics, Inc. 2026财年Q1营收0.34亿美元，同比增长55.5%；归母净利润亏损0.69亿美元，同比亏损扩大5.6%
华盛资讯4月30日讯，Kymera Therapeutics, Inc.公布2026财年Q1业绩，公司Q1营收0.34亿美元，同比增长55.5%，归母净利润亏损0.69亿美元，同比亏损扩大5.6%。
04-30 21:04
财报速睇 | Kymera Therapeutics, Inc. 2026财年Q1营收0.34亿美元，同比增长55.5%；归母净利润亏损0.69亿美元，同比亏损扩大5.6%
华盛资讯4月30日讯，Kymera Therapeutics, Inc.公布2026财年Q1业绩，公司Q1营收0.34亿美元，同比增长55.5%，归母净利润亏损0.69亿美元，同比亏损扩大5.6%。
04-30 19:35
Kymera Therapeutics Q1 EPS $(0.71) Beats $(0.88) Estimate, Sales $34.365M Beat $8.614M Estimate
Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.88) by 19.32 percent. This is a 13.41 percent increase over losses of $(0.82) per share
04-30 19:21
Earnings Scheduled For April 30, 2026
Companies Reporting Before The Bell • Sonic Automotive (NYSE:SAH) is projected ...
04-30 19:11
